|1.||Zhao, Ming: 3 articles (02/2015 - 12/2012)|
|2.||Freissmuth, Michael: 2 articles (09/2008 - 03/2008)|
|3.||Pak, Koon: 1 article (12/2015)|
|4.||Staelens, Steven: 1 article (12/2015)|
|5.||Verhaeghe, Jeroen: 1 article (12/2015)|
|6.||Wyffels, Leonie: 1 article (12/2015)|
|7.||Vangestel, Christel: 1 article (12/2015)|
|8.||Stroobants, Sigrid: 1 article (12/2015)|
|9.||Rapic, Sara: 1 article (12/2015)|
|10.||Elvas, Filipe: 1 article (12/2015)|
|1.||Cystic Fibrosis (Mucoviscidosis)
09/01/2008 - "Our data suggest that duramycin qualifies for intrapulmonary administration in cystic fibrosis (CF) patients."
03/01/2008 - "The amphipathic peptide duramycin is in clinical development for the treatment of cystic fibrosis. "
12/01/2010 - "The lantibiotic duramycin (Moli1901, Lancovutide) has been suggested as a drug of choice in the treatment for cystic fibrosis (CF). "
12/01/2010 - "Effect of duramycin on chloride transport and intracellular calcium concentration in cystic fibrosis and non-cystic fibrosis epithelia."
09/01/2008 - "Duramycin (Moli1901) is being developed for the treatment of reduced mucociliary clearance in cystic fibrosis. "
11/24/2015 - "The inhibitory effect of Duramycin is specific: it inhibits TIM1-mediated, but not L-SIGN-mediated, virus infection, and it does so by blocking virus attachment to TIM1. "
04/01/2015 - "The success of these agents as a novel treatment of MDR infections is exemplified by: the clinical development of MU1140 (mutacin 1140) and NAI-107 (microbisporicin), which are in late pre-clinical trials against gram-positive bacteria; NVB302 that has completed Phase I clinical trials for the treatment of Clostridium difficile infections and; duramycin that has completed Phase II clinical trials in the treatment of cystic fibrosis. "
01/01/2013 - "The objective of this study was to investigate the capability of (99m)Tc-labeled duramycin in detecting ischemia-reperfusion injury in rat brain after middle cerebral artery (MCA) occlusion. "
02/01/2015 - "The goal of the current study was to investigate the clearance kinetics of (99m)Tc-labeled duramycin in a large animal model (normal pigs) and to assess its uptake in the heart using a pig model of myocardial ischemia-reperfusion injury. "
01/01/2013 - "Imaging of rat cerebral ischemia-reperfusion injury using(99m)Tc-labeled duramycin."
|4.||Myocardial Ischemia (Ischemic Heart Diseases)
12/01/2015 - "We investigated the usefulness of [(99m)Tc]duramycin for monitoring early response to cancer therapy in mice, with an eye towards clinical translation. "
12/01/2015 - "Characterization of [(99m)Tc]Duramycin as a SPECT Imaging Agent for Early Assessment of Tumor Apoptosis."
12/01/2015 - "[(99m)Tc]Duramycin can be used to detect early chemotherapy-induced tumor cell death, and thus, may be a prospective candidate for clinical SPECT imaging of tumor response to therapy."
12/01/2015 - "[(99m)Tc]Duramycin uptake in vivo following therapy increased significantly in apoptotic irinotecan-treated tumors (p = 0.008). "
04/01/2011 - "When biotinylated duramycin was intravenously injected into tumor-bearing mice, it preferentially localized to the luminal surface of the vascular endothelium. "
|5.||Caspase 3 (Caspase-3)
|1.||Drug Therapy (Chemotherapy)